Longeveron (NASDAQ:LGVN) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Longeveron (NASDAQ:LGVN) in a research note published on Friday morning,Benzinga reports. The firm currently has a $10.00 target price on the stock.

A number of other brokerages also recently issued reports on LGVN. Roth Mkm started coverage on shares of Longeveron in a research report on Friday, December 6th. They set a “buy” rating and a $10.00 price objective for the company. Roth Capital raised Longeveron to a “strong-buy” rating in a report on Thursday, December 5th.

Longeveron Trading Up 5.1 %

Shares of NASDAQ LGVN opened at $1.85 on Friday. Longeveron has a 12-month low of $0.77 and a 12-month high of $6.40. The firm has a market capitalization of $27.62 million, a price-to-earnings ratio of -0.29 and a beta of 0.37. The firm has a 50 day moving average of $1.60 and a 200 day moving average of $1.84.

Institutional Trading of Longeveron

Several institutional investors and hedge funds have recently modified their holdings of LGVN. Jane Street Group LLC purchased a new stake in Longeveron in the 4th quarter worth $35,000. Northern Trust Corp bought a new position in shares of Longeveron in the fourth quarter worth about $31,000. Virtu Financial LLC bought a new position in shares of Longeveron in the fourth quarter worth about $53,000. Geode Capital Management LLC grew its position in shares of Longeveron by 316.0% during the third quarter. Geode Capital Management LLC now owns 128,947 shares of the company’s stock worth $250,000 after purchasing an additional 97,953 shares in the last quarter. Finally, State Street Corp bought a new stake in Longeveron during the 3rd quarter valued at approximately $29,000. 10.01% of the stock is currently owned by institutional investors.

Longeveron Company Profile

Longeveron Inc, a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors.